Legal Disclaimer

All products on this site are for research and development, laboratory, or analytical use only; they are not for human consumption, medical, diagnostic, cosmetic, veterinary, or The statements and products have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Vitacelle Labs is not a compounding pharmacy or chemical compounding facility as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, nor an outsourcing facility as defined under section 503B.

MAZDUTIDE

$59.99 USD

~~$79.99 USD~~ $59.99 USD

Sale Sold out

Mazdutide (also known as a GLP-1R/GCGR dual agonist) is a novel long-acting peptide drug candidate that simultaneously targets the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). By mimicking the synergistic effects of the native hormones GLP-1 and glucagon, it exhibits multi‑faceted potential in regulating blood glucose, promoting energy expenditure, and improving metabolic health. This high‑purity synthetic peptide is designed for mechanistic studies of metabolic diseases and as a platform for developing new anti‑diabetic/anti‑obesity therapeutics.

size 10mg

Save up to 15% when you buy more!

Quantity	Discount	Price
1	0%	$59.99
2 - 5	5%	$56.99
6 - 10	10%	$53.99
11 - 15	15%	$50.99

Product details

Dual‑Target Design: A single molecule activates both GLP‑1R and GCGR, enabling synergistic glucose control and energy metabolism regulation

Long‑Acting Modification: Fatty acid side‑chain conjugation or fusion protein technology extends half‑life, supporting once‑weekly dosing in experimental models

High Purity & Bioactivity: Solid‑phase synthesized and chromatographically purified (HPLC ≥98%), with bioactivity validated by cellular receptor activation assays

Metabolic Research Ready: Suitable for long‑term metabolic phenotyping studies in rodents and non‑human primates

Mechanism of action

GLP‑1R Pathway Activation:Enhances glucose‑dependent insulin secretion and suppresses glucagon releaseDelays gastric emptying, increases satiety, and reduces food intake
GCGR Pathway Co‑Activation:Promotes hepatic glycogenolysis and gluconeogenesis, balanced by GLP‑1‑mediated glucose‑lowering effectsIncreases energy expenditure and lipid oxidation, improving hepatic lipid metabolism
Integrated Metabolic Benefits:Synergistic actions lead to more pronounced body weight reduction, improved insulin sensitivity, and decreased hepatic fat accumulation

Usage Guidelines (Research UseOnly):

Reconstitute using sterile saline or a specified buffer.

Store lyophilized powder sealed and protected from light at -20°C or below. After reconstitution, aliquot and freeze to avoid repeated freeze-thaw cycles to maintain peptide stability.

Suitable for in vitro wound healing assays, cell migration/proliferation analyses, or subcutaneous/intramuscular injection studies in animal models.

Specific dosage, frequency, and administration routes should be optimized based on published literature and preliminary experimental results, while strictly adhering to animal research ethical guidelines.

Packaging Instructions

Packaging Note: This product is supplied in a sealed, sterile glass vial without any pre‑printed labels. This design supports institutional compliance protocols and allows researchers to apply custom labels that align with specific experimental protocols, ethical approvals, and local regulations. A separate document containing complete product details (name, batch number, purity, content, COA reference, etc.) is included for label customization and record‑keeping.

View full details